Onconova Therapeutics Stock News

NEWTOWN, Pa., Sept. 28, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a clinical-stage biopharmaceutical company focused on discovering and developing novel pro

Investors need to pay close attention to Onconova (ONTX) stock based on the movements in the options market lately.

Onconova Therapeutics Inc (NASDAQ: ONTX) has priced an underwritten public offering of 5 million shares at $4.20 for gross proceeds of $21 million. The offer price represents an almost 17% discount

NEWTOWN, Pa., Sept. 24, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat

NEWTOWN, Pa., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ: ONTX) (“Onconova”), a biopharmaceutical company focused on discovering and developing novel products to treat

Onconova (ONTX) is developing a combination of its rigosertib plus Bristol-Myers' Opdivo for treating cancer with solid tumors. Preliminary data from the phase I/II study demonstrates disease control

The stock price of Onconova Therapeutics Inc (NASDAQ: ONTX) is trading at over 25% during intraday trading today. This is why it happened.

Onconova Therapeutics, Inc. (NASDAQ:ONTX) shares are trading higher after the company reported preliminary data from a Phase 1/2 a trial of rigosertib plus immune checkpoint inhibitor nivolumab, whic

Today, Oncova Therapeutics announced some positive preliminary trial results from one of its core cancer drugs, sending ONTX stock higher. The post ONTX Stock Is Soaring 25% on This Big Cancer Drug Up

Onconova Therapeutics Inc (NASDAQ: ONTX) has announced preliminary data from Phase 1/2a trial of rigosertib plus Bristol-Myers Squibb Co's (NYSE: BMY) Opdivo (nivolumab) in advanced KRAS mutated no

Onconova Therapeutics, Inc. (ONTX) delivered earnings and revenue surprises of 3.57% and 35.71%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the sto

Onconova Therapeutics, Inc. (ONTX) CEO Steve Fruchtman on Q2 2021 Results - Earnings Call Transcript

Shares of Onconova Therapeutics (NASDAQ:ONTX) moved higher by 2.1% in after-market trading after the company reported Q2 results. Quarterly Results Earnings per share fell 575.00% over the past year t

Conference call and live webcast at 4:30 p.m. ET today Conference call and live webcast at 4:30 p.m. ET today

Onconova Therapeutics, Inc. (ONTX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.